Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor |
Baylor College of Medicine / William Decker, PhD |
Reach Grants |
2013 |
Texas |
B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers
|
University of Texas Southwestern Medical Center / James Amatruda, MD, PhD |
Reach Grants |
2013 |
Texas |
Targeting Novel Pediatric-Specific FLT3 Mutations |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD |
Reach Grants |
2015 |
Washington |
Development of a Novel Mer Tyrosine Kinase Inhibitor for Treatment of ALL |
University of Colorado Denver / Doug Graham, MD, PhD |
Reach Grants |
2013 |
Colorado |
Novel Strategy for Reducing Radiation-Induced Morbidity and Treating Recurrent Medulloblasoma |
Massachusetts General Hospital / Rakesh Jain, PhD |
Reach Grants |
2013 |
Massachusetts |
Targeting a Novel Epigenetic Signature in Diffuse Intrinsic Pontine Gliomas |
New York University School of Medicine / Danny Reinberg, PhD |
Reach Grants |
2019 |
New York |
Dual PTK7/GD2 Gamma Delta CAR T Cell Therapy for Neuroblastoma |
Emory University / Kelly Goldsmith, MD & H. Trent Spencer, PhD & Chris B. Doering, PhD |
Reach Grants |
2021 |
Georgia |
Immunoglobulin High-Throughput Sequencing for Refining Risk Stratification in Infant B-ALL |
University of Rochester / Carol Fries Simpson, MD |
Reach Grants |
2023 |
New York |
Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma |
Children’s Hospital Los Angeles / Jesse Berry, MD |
Reach Grants |
2023 |
California |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |